Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Bertamini

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Annals of Translational Medicine|July 11, 2020
Checkpoint inhibitors and myeloma: promises, deadlocks and new directionsLuca Bertamini, Francesca Gay
Frontiers in Oncology|June 1, 2022
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World ResultsLuca Bertamini, Giuseppe Bertuglia, Stefania Oliva
Current Hematologic Malignancy Reports|May 5, 2021
MRD Assessment in Multiple Myeloma: Progress and ChallengesLuca Bertamini, Mattia D'Agostino, Francesca Gay
Expert Opinion on Investigational Drugs|May 22, 2020
New drugs in early development for treating multiple myeloma: all that glitters is not goldLuca Bertamini, Francesca Bonello, Mario Boccadoro, et al.
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Cancers|December 19, 2019
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic StrategiesMattia D'Agostino, Luca Bertamini, Stefania Oliva, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
When and How to Treat Relapsed Multiple MyelomaNitya Nathwani, Luca Bertamini, Rahul Banerjee, et al.
Nature Reviews. Cancer|October 16, 2024
New horizons in our understanding of precursor multiple myeloma and early interceptionDavid M Cordas Dos Santos, Rosa Toenges, Luca Bertamini, et al.
Geroscience|October 26, 2024
Clonal hematopoiesis in cardiovascular aging: Insights from the verona heart studyKatarzyna Malgorzata Kwiatkowska, Nicola Martinelli, Luca Bertamini, et al.
BMC Cancer|November 17, 2018
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemiaLuca Bertamini, Jacopo Nanni, Giovanni Marconi, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Annals of Translational Medicine|July 11, 2020
Checkpoint inhibitors and myeloma: promises, deadlocks and new directionsLuca Bertamini, Francesca Gay
Frontiers in Oncology|June 1, 2022
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World ResultsLuca Bertamini, Giuseppe Bertuglia, Stefania Oliva
Current Hematologic Malignancy Reports|May 5, 2021
MRD Assessment in Multiple Myeloma: Progress and ChallengesLuca Bertamini, Mattia D'Agostino, Francesca Gay
Expert Opinion on Investigational Drugs|May 22, 2020
New drugs in early development for treating multiple myeloma: all that glitters is not goldLuca Bertamini, Francesca Bonello, Mario Boccadoro, et al.
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Cancers|December 19, 2019
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic StrategiesMattia D'Agostino, Luca Bertamini, Stefania Oliva, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
When and How to Treat Relapsed Multiple MyelomaNitya Nathwani, Luca Bertamini, Rahul Banerjee, et al.
Nature Reviews. Cancer|October 16, 2024
New horizons in our understanding of precursor multiple myeloma and early interceptionDavid M Cordas Dos Santos, Rosa Toenges, Luca Bertamini, et al.
Geroscience|October 26, 2024
Clonal hematopoiesis in cardiovascular aging: Insights from the verona heart studyKatarzyna Malgorzata Kwiatkowska, Nicola Martinelli, Luca Bertamini, et al.
BMC Cancer|November 17, 2018
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemiaLuca Bertamini, Jacopo Nanni, Giovanni Marconi, et al.
Pageof 3